Vaccine platform
Develops vectors for vaccine delivery and development.
Greffex
Compiled from public sources
Unclaimed business
Unclaimed
- Claim to manage details & reply to reviews
- Pro profile & priority placement
- Reedleys Recognition & certificate
About Greffex
Greffex's fully deleted, helper-independent vector platform is designed to deliver vaccines without contaminating helper or recombinant replicating viruses. The company develops genetic engineering technology for vaccine and gene therapy applications. Its vaccine pipeline includes candidates for H5N1 avian flu, universal flu, anthrax, Ebola, dengue, Zika, and Lyme disease. Greffex says its vectors can be stored at room temperature and manufactured using a standardized process. The platform also has applications in cancer treatments and transplantation therapies. Greffex began with gene therapy and transplantation work before shifting its focus to vaccines. Its H5N1 candidate is described as entering Phase 1/2a clinical trials, while its universal flu candidate is in preclinical development.
Disclosure: Profile information has been compiled from publicly available sources and has not yet been verified by the business.
Representative photos. Illustrative images for this category, not photos of Greffex and not provided by the business.
Highlights
Gene therapy
Platform applications include gene therapy treatments.
Vaccine pipeline
Candidates include H5N1, universal flu, and Lyme disease.
Greffex Reviews
No reviews yet — be the first to review Greffex.
Write a review
Sign in to write a review
or get a one-click link by email
No password needed. We only use your email to confirm the review is genuine.